Table 4 Univariate analysis of predictive factors of poor agreement between D^{Post-treatment-R} and D^Predicitve-D for Lesion, TL and NTL

Sex

Male vs. Female

0.23 (0.14-0.34) vs 0.22 (0.13-0.33)

0.50

0.29 (0.20-0.37) vs 0.25 (0.17-0.29)

0.22

0.27 (0.19-0.36) vs 0.27 (0.22-0.40)

0.79

Age (y)

> 73 vs ≤73

0.21 (0.14-0.33) vs 0.23 (0.14-0.34)

0.54

0.25 (0.16-0.33) vs 0.26 (0.20-0.34)

0.61

0.24 (0.19-0.43) vs 0.28 (0.24-0.32)

0.47

Previous Liver surgery

Yes vs No

0.26 (0.15-0.34) vs 0.22 (0.14-0.32)

0.74

0.28 (0.18-0.39) vs 0.26 (0.17-0.30)

0.53

0.24 (0.20-0.33) vs 0.28 (0.19-0.39)

0.70

Previous Bevacizumab

Yes vs No

0.19 (0.13-0.34) vs 0.26 (0.17-0.33)

0.07

0.24 (0.17-0.33) vs 0.27 (0.19-0.33)

0.98

0.27 (0.18-0.33) vs 0.28 (0.23-0.43)

0.19

Delay predictive / post-treatment dosimetry (d)

> 9 vs ≤9

0.26 (0.17-0.38) vs 0.19 (0.12-0.30)

0.003

0.28 (0.22-0.37) vs 0.22 (0.15-0.27)

0.03

0.33 (0.28-0.41) vs 0.22 (0.18-0.28)

0.004

Net administered activity (MBq)

> 1262 vs ≤1262

0.20 (0.13-0.34) vs 0.24 (0.16-0.33)

0.49

0.25 (0.20-0.35) vs 0.26 (0.17-0.33)

0.64

0.26 (0.19-0.35) vs 0.28 (0.21-0.41)

0.50

Lesion Volume (ml)

> 5.8 vs ≤5.8

0.23 (0.15-0.32) vs 0.21 (0.13-0.34)

0.51

TL Volume (ml)

> 73.34 vs ≤73.34

0.28 (0.16-0.37) vs 0.26 (0.20-0.30)

0.40

NTL Volume (ml)

> 1354 vs ≤1354

0.29 (0.21-0.41) vs 0.27 (0.20-0.31)

0.37

Type of targeting

Whole liver single injection

0.17 (0.12-0.28)

0.02

0.20 (0.15-0.28)

0.65

0.23 (0.17-0.33)

0.42

Whole Liver injection left and right lobes separately

0.24 (0.14-0.35)

0.27 (0.17-0.37)

0.31 (0.19-0.41)

Uni-lobar

0.26 (0.18-0.33)

0.27 (0.22-0.33)

0.28 (0.24-0.38)